Epimedium aglycone derivatives, their preparation methods and uses

By synthesizing icariin derivatives and binding them with PEG, their solubility and bioavailability are improved, solving the problem of poor solubility of icariin, achieving effective treatment of asthma and bone marrow suppression, reducing toxic side effects, and improving safety.

CN110358075BActive Publication Date: 2026-11-10LUNAN PHARMA GROUP CORPORATION
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN201810254217.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2018-03-26
Publication Date
2026-11-10
Estimated Expiration
2038-03-26

AI Technical Summary

Technical Problem

Icariin has poor solubility and low oral bioavailability, which limits its pharmacological activity. Furthermore, existing compounds have side effects and hepatotoxicity when used to treat asthma and myelosuppression caused by chemotherapy or radiotherapy.

Method used

Icariin derivatives were synthesized and their pharmaceutically acceptable salts were prepared. Solubility was improved by conjugation with PEG, and the compounds with excellent solubility and bioavailability were synthesized using specific condensing agents and reaction conditions.

Benefits of technology

It significantly improved the solubility and bioavailability of icariin, enhanced the therapeutic effect on asthma, reduced the side effects of bone marrow suppression caused by chemotherapy or radiotherapy, and had no obvious toxicity, thus improving clinical safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN110358075B_ABST
    Figure CN110358075B_ABST
Patent Text Reader

Abstract

This invention belongs to the field of medicinal chemistry, specifically relating to icariin derivatives, such as formula W-1B, their pharmacologically acceptable salts and methods for their preparation, and their use in the preparation of medicaments for treating asthma or myelosuppression.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of medicinal chemistry, specifically relating to icariin derivatives and their pharmacologically acceptable salts, as well as their preparation methods and applications. Background Technology

[0002] Icaritin (ICT) is a polyhydroxyflavonoid monomer from Epimedium, a plant belonging to the genus Epimedium in the family Berberidaceae. Its structural formula is as follows:

[0003]

[0004] Icariin can be isolated from icariin or its in vivo metabolites (Sun Pengyue, Xu Ying, Wen Ye et al., Chemical constituents of Korean icariin, Chinese Journal of Phytochemistry, 1998, 8(2): 122-125; Liu Tiehan, Wang Yi, Wu Lijun et al., Study on intestinal bacterial metabolism of icariin I. Metabolic transformation of icariin by intestinal bacteria, 2000, 31(11): 834-837), or obtained by enzymatic hydrolysis of icariin (Ye Haiyong, Liu Jian, Lou Yijia, Preparation of icariin derivatives and its estrogen-like effects, Journal of Zhejiang University, 2005, 34(2): 131-136).

[0005] Literature reports that icariin has an anti-apoptotic effect on Aβ-induced apoptosis in primary cultured rat neurons (Zhang Xiangnan, Wang Huanhuan, Wang Zhiqiang, et al., Anti-apoptotic effect of icariin on Aβ-induced apoptosis in primary cultured rat neurons, Journal of Zhejiang University, 2007, 36(3): 224-226). Chinese patent CN101836976A discloses that icariin has an anti-tumor angiogenesis effect. Chinese patent CN101428015A discloses that icariin has an anti-endotoxemia effect. Chinese patent CN101284000A discloses that icariin has a role in preventing and treating obesity or fatty liver. Chinese patent CN1869204A discloses the use of icariin in inducing in vitro directed differentiation of stem cells.

[0006] Icariin possesses a wide range of pharmacological activities, but its solubility is poor. It is slightly soluble in dichloromethane and ethyl acetate, almost insoluble in methanol, anhydrous ethanol, and water, and almost insoluble or insoluble in various pH buffers. Icariin has low oral bioavailability. Summary of the Invention

[0007] This invention provides an icariin derivative with the structure shown in formula W-1B:

[0008] Pharmaceutically acceptable salts of compounds of formula W-1B;

[0009] Wherein, m and n are independently selected from integers from 0 to 6;

[0010] The molecular weight of the PEG is selected from 400-20000; preferably 1000-10000.

[0011] In some specific embodiments, PEG is selected from PEG400, PEG600, PEG1000, PEG2000, PEG3000, PEG4000, PEG6000, PEG10000, or PEG20000.

[0012] Furthermore, m and n are independently selected from integers from 0 to 4.

[0013] In some specific embodiments, the compound of formula W-1B is specifically compound of formula W-1B-22:

[0014]

[0015] The above-mentioned compound W-1B can be synthesized, but is not limited to, according to the following scheme, with the following steps:

[0016] 1) Boc-ICT reacts with haloalcohols to give 1;

[0017]

[0018] 2) Compound 1 reacts with Boc2O to give compound 2;

[0019]

[0020] 3) Compound 2 was deprotected to obtain compound 3

[0021]

[0022] 4) PEG and The reaction yields 4;

[0023]

[0024] The m is selected from integers from 0 to 6;

[0025] 5) Compound 3 and compound 4 react in the presence of a condensing agent to form compound 5:

[0026]

[0027] 6) Compound 5 was deprotected to give compound W-1B;

[0028]

[0029] The condensation process may use a condensing agent; the condensing agent is selected from at least one of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride / 4-dimethylaminopyridine (EDCI / DMAP), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride / 1-hydroxybenzotriazole / N,N-diisopropylethylamine (EDCI / HOBT / DIPEA), 2-(7-benzotriazole oxide)-N,N,N',N'-tetramethylurea hexafluorophosphate / N,N-diisopropylethylamine (HATU / DIPEA), and dicyclohexylcarbodiimide / 4-dimethylaminopyridine (DCC / DMAP).

[0030] The amount of the condensing agent used is 0.1-25 eq;

[0031] The reaction temperature during the condensation reaction is 0-70℃.

[0032] In some reactions, alkaline conditions are required, wherein the base is selected from at least one of triethylamine, pyridine, sodium carbonate, sodium hydroxide, sodium bicarbonate, potassium carbonate, and sodium sulfate; the amount used is 0.05-10 eq;

[0033] In some reactions, the reaction is carried out in a solvent selected from, but not limited to, dichloromethane, chloroform, tetrahydrofuran, acetone, acetonitrile, or toluene.

[0034] The present invention also provides a pharmaceutical composition comprising a therapeutically effective amount of the epimedium aglycone derivative of the present invention or a pharmacologically permissible salt thereof. Specifically, the salt is a pharmaceutically acceptable salt. The term "pharmaceutically acceptable" includes that the substance or composition must be chemically or toxicologically suitable in relation to other components of the formulation and the mammal intended for treatment. The salts of the compounds of the present invention also include salts used for the preparation or purification of the compound (formula W-1B) and its intermediates (such as intermediates 2, 4) or for the isolation of enantiomers of the compound (such as intermediate 2), but are not necessarily pharmaceutically acceptable salts.

[0035] If the compounds of the present invention are basic, the desired salt can be prepared by any suitable method provided in the literature, for example, using inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid, etc. Alternatively, organic acids such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, malic acid, 2-hydroxypropionic acid, citric acid, oxalic acid, glycolic acid, and salicylic acid; pyranonic acids such as glucuronic acid and galacturonic acid; α-hydroxy acids such as citric acid and tartaric acid; amino acids such as aspartic acid and glutamic acid; aromatic acids such as benzoic acid and cinnamic acid; sulfonic acids such as p-toluenesulfonic acid, benzenesulfonic acid, methanesulfonic acid, ethanesulfonic acid, trifluoromethanesulfonic acid, etc., or combinations thereof, can be used.

[0036] If the compounds of the present invention are acidic, the desired salts can be prepared by suitable methods, such as using inorganic or organic bases, such as ammonia (primary, secondary, and tertiary), alkali metal hydroxides, ammonium, salts of N+(R14)4, and alkaline earth metal hydroxides, etc. Suitable salts include, but are not limited to, organic salts derived from amino acids, such as glycine and arginine; ammonia, such as primary, secondary, and tertiary ammonia; salts of N+(R14)4, such as R14 being H, C1-4 alkyl, C6-10 aryl, C6-10 aryl-C1-4 alkyl, etc.; and cyclic ammonia, such as piperidine, morpholine, and piperazine, etc.; and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium. This also includes suitable, non-toxic ammonium, quaternary ammonium salts, and amine cations that resist the formation of equilibrium ions, such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, C1-8 sulfonates, and aromatic sulfonates. As used in the invention, "pharmaceutically acceptable salts" refers to the organic and inorganic salts of the compounds of the invention. Pharmaceutically acceptable salts are well-known in the field, as described in the literature: SMBerge et al., describe epharm-aceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66:1-19, 1977. Pharmaceutically acceptable non-toxic acid-forming salts include, but are not limited to, inorganic acid salts formed by reaction with amino groups, such as hydrochlorides, hydrobromic acids, phosphates, sulfates, perchlorates, and organic acid salts such as acetates, oxalates, maleates, tartrates, citrates, succinates, malonates, or these salts obtained by other methods described in the literature, such as ion exchange. Other pharmaceutically acceptable salts include adipate, malate, 2-hydroxypropionate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, cyclopentylpropionate, digluconate, dodecyl sulfate, ethanesulfonate, formate, transbutenedioic acid, gluconate, glycerophosphate, gluconate, hemisulfate, heptaate, hexanoate, hydroiodate, 2-hydroxy-ethanesulfonate, lacturonate, lactate, laurate, lauryl sulfate, malate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, palmitate, pyruvate, pectinate, persulfate, 3-phenylpropionate, picrate, pentanoate, propionate, stearate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, etc. Salts obtained by using appropriate bases include salts of alkali metals, alkaline earth metals, ammonium, and N+(C1-4 alkyl)4.

[0037] Pharmaceutical compositions. These pharmaceutical compositions can be formulated into dosage forms such as solid oral preparations, liquid oral preparations, and injections. For example, the pharmaceutical composition can be administered orally in the form of tablets, capsules, pills, powders, sustained-release formulations, solutions, or suspensions; the pharmaceutical composition can also be administered parenterally in the form of sterile solutions, suspensions, or emulsions; the pharmaceutical composition can also be administered topically in the form of ointments or creams; and the pharmaceutical composition can also be administered rectally in the form of suppositories. The pharmaceutical composition can be formulated into unit dosage forms suitable for precise single-dose administration. The solid and liquid oral preparations include: tablets, dispersible tablets, enteric-coated tablets, chewable tablets, orally disintegrating tablets, capsules, syrups, granules, oral solutions, and injections. Parenteral preparations can be formulated into dosage forms such as injections and lyophilized powders for injection; topical preparations can be formulated into creams, ointments, patches, sprays, etc., but are not limited to these. The oral preparations used may contain, for example, one or more colorants, sweeteners, flavoring agents, and / or preservatives.

[0038] Lactose or starch can be used as the carrier for the solid oral formulation; gelatin, methylcellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, starch paste, etc., can be used as binders; starch, sodium carboxymethyl cellulose, sodium carboxymethyl starch, low-substituted hydroxypropyl methylcellulose, crospovidone, microcrystalline cellulose, etc., can be used as disintegrants; talc, micronized silica gel, glyceryl stearate, calcium stearate, or magnesium stearate can be used as anti-adhesives and lubricants. Suitable pharmaceutically acceptable excipients for tablet formulations include, for example, inert diluents such as lactose, sodium carbonate, calcium phosphate, or calcium carbonate; granulating and disintegrants such as corn starch and alginate; binders such as starch; lubricants such as magnesium stearate, stearic acid, or talc; preservatives such as ethyl or propylparaben; and antioxidants such as ascorbic acid. Tablet formulations may be uncoated or coated to alter their disintegration and subsequent absorption of the active ingredient in the gastrointestinal tract, or to improve their stability and / or appearance. In either case, conventional coating agents and methods well known in the art may be used.

[0039] The method for preparing the solid oral dosage form includes the following steps: mixing the active ingredient with a carrier and selectively with a disintegrant additive, then granulating the mixture with an aqueous, alcoholic, or aqueous alcoholic solution of a binder using a wet or dry method in a suitable device, and subsequently adding other disintegrants, lubricants, and anti-adhesion agents to prepare a suitable formulation.

[0040] The pharmaceutical compositions of the present invention can also be in the form of an oil-in-water emulsion. The oil phase can be a vegetable oil, such as olive oil or peanut oil, or a mineral oil, such as liquid paraffin, or a mixture thereof. Suitable emulsifiers can be, for example, natural gums such as gum arabic or tragacanth gum, natural phospholipids such as soybean lecithin, and esters or metaesters derived from fatty acids and hexitan anhydrides (e.g., sorbitan monooleate), and condensation products of said metaesters with ethylene oxide. For example, the series of compounds of the present invention can also be administered orally. Preferred parenteral administration is by injection. Syrups and elixirs can be formulated with sweeteners (e.g., glycerol, propylene glycol, sorbitol, aspartame, or sucrose) and may also contain modifiers, preservatives, flavoring agents, and / or coloring agents.

[0041] The pharmaceutical composition may also be in the form of a sterile aqueous or oily suspension for injection, which can be formulated using one or more suitable dispersants or wetting agents and suspending agents as described above, according to known methods. The sterile injectable formulation may also be a sterile aqueous or oily suspension for injection in a non-toxic, parenteral-acceptable diluent or solvent, such as a solution in 1,3-butanediol. The amount of active ingredient mixed with one or more excipients to prepare a single-dose form can be determined depending on the host being treated and the specific route of administration. For example, formulations for oral administration to humans generally contain, for example, 0.5 mg to 2 g of the active ingredient and appropriate and conventional amounts of excipients (approximately 5-98% of the total weight of the composition). A unit formulation generally contains approximately 1 mg to 500 mg of the active ingredient.

[0042] In this invention, the PEG+number format refers to PEG with a molecular weight of that number, such as PEG1000, which means PEG with a molecular weight of 1000. All molecular weights mentioned in this invention are weight-average molecular weights.

[0043] Another object of the present invention is to provide a pharmaceutical composition comprising the epimedium aglycone derivative of the present invention or a pharmacologically acceptable salt thereof.

[0044] Another object of the present invention is to provide the use of icariin derivatives and their pharmacologically acceptable salts in the preparation of medicaments for the treatment of asthma or myelosuppression.

[0045] The icariin derivatives of this invention exhibit significantly better therapeutic effects than icariin itself for asthma. Furthermore, the icariin derivatives of this invention show significantly better therapeutic effects than icariin itself for bone marrow suppression induced by radiotherapy or chemotherapy. Finally, the bioavailability of the icariin derivatives of this invention is significantly better than that of icariin itself, indicating that the compounds of this invention possess significant technical advantages in terms of drug-likeness.

[0046] The icariin derivative of this invention exhibits significantly superior therapeutic effects on asthma compared to the compound of Formula I. The icariin derivative of this invention also shows significantly superior therapeutic effects on bone marrow suppression induced by radiotherapy or chemotherapy compared to the compound of Formula I. Furthermore, the bioavailability of the icariin derivative of this invention is significantly better than that of the compound of Formula I, indicating a clear technical advantage in terms of drug-likeness. More importantly, long-term toxicity studies revealed that the compound of Formula I exhibits certain hepatotoxicity and nephrotoxicity, and causes mammary hyperplasia in female rats, while the compound of this invention shows no significant toxicity, demonstrating higher clinical safety compared to the compound of Formula I.

[0047] Compound I is compound 5 from the literature (Dell'Agli M, Galli GV, Dal CE, et al. Potent inhibition of human phosphodiesterase-5 by icariin derivatives.[J]. Journal of Natural Products, 2008, 71(9):1513-1517.). The structural formula of compound I is as follows:

[0048] Detailed Implementation

[0049] The following detailed embodiments illustrate the present invention. However, these embodiments should not be construed as limiting the invention. Various substitutions or modifications made by those skilled in the art based on common technical knowledge and conventional methods without departing from the above-described spirit of the invention are all included within the scope of the invention.

[0050] Example 1

[0051]

[0052] Weigh 500 mg (1.1 mmol) of Boc-protected icariin (Boc-ICT) into a 100 ml round-bottom flask, add 20 ml of acetone as solvent, add 188 mg (1.4 mmol) of potassium carbonate and 0.1 ml (1.4 mmol) of 2-bromoethanol, reflux until the reaction is complete, evaporate the solvent under reduced pressure, dissolve in ethyl acetate, and purify by column chromatography to obtain solid product 1.

[0053] MS of solid product 1: 512.6.

[0054] Example 2

[0055]

[0056] 1500 mg (1.4 mmol) of solid product 1 was dissolved in 15 mL of dichloromethane, and 265 mg (1.4 mmol) of BOC2O-2, 240 mg (1.5 mmol) of carbodiimide (EDCI), and 25 mg (0.2 mmol) of 4-dimethylaminopyridine (DMAP) were added. The mixture was stirred at room temperature for 1 h until the reaction was complete. The solvent was evaporated under reduced pressure, dissolved in ethyl acetate, and purified by column chromatography to give solid product 2 in 85% yield.

[0057] MS of solid product 2: 597.0.

[0058] 1 H NMR (300MHz, CDCl3): 12.03 (s, 1H), 8.90 (s, 6H), 7.97 (d, J = 8.7Hz, 2H), 7.2 (d, J = 9.0Hz, 2H), 6.94 (s,1H),3.97(s,3H),3.68(s,2H),3.47(s,1H),2.83(s,1H),1.63(s,12H).ESI-MS(m / z):511[M+H] + .

[0059] Example 3

[0060]

[0061] 2 mmol of the product was placed in a 100 ml round-bottom flask, 50 ml of dichloromethane was added as solvent, the mixture was kept at -10 °C, 3 ml of trifluoroacetic acid was added, and after the reaction was complete, the product was separated by column chromatography to obtain solid product 3, with a yield of 91%.

[0062] MS of solid product 3: 496.7.

[0063] Example 4

[0064]

[0065] Weigh 2 g (1 mmol) of PEG2000 (in Examples 7-14, this can be replaced with PEG400, PEG600, PEG1000, PEG2000, PEG3000, PEG4000, PEG6000, PEG10000, or PEG20000, with corresponding changes in mass and solvent volume) into a 100 ml round-bottom flask. Add 15 ml of chloroform as solvent, along with 1 g (10 mmol) of succinic anhydride and 4 ml of pyridine. React at 70 °C. After the reaction is complete, evaporate the solvent to dryness, add saturated sodium bicarbonate solution, adjust the pH to acidic with hydrochloric acid, extract three times with dichloromethane, combine the dichloromethane layers, dry, evaporate to dryness, and recrystallize from diethyl ether to obtain 1.6 g of a white solid intermediate, yield 73%.

[0066] MS of solid product 4: 292.5.

[0067] Example 5

[0068]

[0069] Weigh 90 mg (0.36 mmol) of solid product 3 and 0.1 mmol of solid product 4 into a 100 mL round-bottom flask. Add 20 mL of dry dichloromethane as solvent. Add 41 mg (0.2 mmol) of DCC and 25 mg (0.2 mmol) of DMAP while stirring at room temperature. After the reaction is complete, filter, wash with water, dry the organic phase with anhydrous sodium sulfate, and separate by column chromatography (dichloromethane:acetone = 40:1-10:1 gradient elution) to give yellow solid 5, yield 78%.

[0070] Example 6: Synthesis of compound W-1B-22.

[0071]

[0072] 5 mmol of the product was placed in a 100 ml round-bottom flask, 15 ml of dichloromethane was added as a solvent, the mixture was cooled in an ice bath, 5 ml of trifluoroacetic acid was added, and after the reaction was complete, the product was separated by column chromatography to obtain the solid product W-1B-22, specifically W-1B-22-2000, with a yield of 91%.

[0073] MS of solid product W-1B-22: 3050.0.

[0074] Examples 7-14

[0075] The PEG used in Example 2 was PEG400, PEG600, PEG1000, PEG3000, PEG4000, PEG6000, PEG10000, or PEG20000, respectively. The other steps were repeated to obtain the products, as shown in Table 1.

[0076] Table 1 Examples 7-14 and their products

[0077]

[0078]

[0079] Example 15 Effect of the compounds of the present invention on chemotherapy-induced bone marrow suppression in tumor-bearing mice

[0080] 1. Model preparation and grouping: Eighty-four Balb / C mice were selected, weighed, and randomly divided into seven groups: normal group, blank control group, icariin group, compound I group, and each group receiving the compound of this invention, with 12 mice in each group. Mice were intraperitoneally injected with 50 mg / kg cyclophosphamide daily for one week, which significantly reduced platelet count. One week before model establishment, each treatment group received the following treatment drugs:

[0081] Normal group: Administered an equal volume of sodium carboxymethyl cellulose;

[0082] Blank control group: Administered an equal volume of sodium carboxymethyl cellulose;

[0083] Epimedium aglycone group: 5 mg / kg epimedium aglycone was administered by gavage;

[0084] Formula I group: 5 mg / kg of Formula I compound was administered by gavage;

[0085] W-1B-22-600 group: 0.5 mg / kg of compound W-1B-22-600 was administered by gavage;

[0086] W-1B-22-4000 group: 0.5 mg / kg of compound W-1B-22-4000 was administered by gavage;

[0087] Group W-1B-22-20000: 0.5 mg / kg of compound W-1B-22-20000 was administered by gavage;

[0088] Compound I is compound 5 from the literature (Dell'Agli M, Galli GV, Dal CE, et al. Potent inhibition of human phosphodiesterase-5 by icariin derivatives.[J]. Journal of Natural Products, 2008, 71(9):1513-1517.). The structural formula of compound I is as follows:

[0089]

[0090] Each treatment group was administered the drug once daily and fed normally. After 3 weeks of continuous administration, mice were anesthetized, blood was collected, and white blood cell and platelet counts were measured to investigate the effects of the compound of this invention on white blood cells and platelets.

[0091] 2. Experimental Results

[0092] Through the effects of the compounds of the present invention on cyclophosphamide-induced white blood cells and platelets in mice in this embodiment (Table 2), it was found that the compounds of the present invention have an unexpected effect in alleviating the bone marrow suppression caused by chemotherapy.

[0093] Compared with the model control group, the total number of white blood cells and the total number of platelets in each compound group of the present invention were increased, and the differences were significant.

[0094] Compared with the icariin group, the total number of white blood cells and platelets in each compound group of the present invention increased significantly.

[0095] Compared with Formula I, the total number of white blood cells and the total number of platelets in each compound group of the present invention are significantly increased.

[0096] Table 2. Effects of each compound on cyclophosphamide-induced leukopenia and thrombocytopenia.

[0097]

[0098]

[0099] Compared with the blank control group, $ p<0.05, $$ p<0.01;

[0100] Compared with the icariin group, # p<0.05, ## p<0.01;

[0101] Compared with Equation I, & p<0.05, && p<0.01.

[0102] Example 16: The compound of the present invention on 60 Effect of Co-irradiated mice on blood cell count

[0103] 1. Model preparation and grouping for drug administration: One hundred Kunming mice were selected. Except for the normal control group (n=10), all other groups of mice were irradiated with 4 Gy. 60 Co radiation was administered via a single whole-body irradiation session with an absorbed dose of 4 Gy at a rate of 0.88 Gy / min. Whole blood cell counts were determined by collecting blood samples from the orbital vein on days 3, 7, and 10 post-irradiation. A white blood cell count below 3.0 × 10⁻⁶ was considered acceptable. 9 / L or platelet count less than 500×10 9 Mice with a weight of / L were removed, and the remaining mice were used for experiments.

[0104] Mice that met the experimental requirements after irradiation were randomly divided into the following groups: model group, icariin group, formula I group, W-1B-22-600 group, W-1B-22-4000 group, and W-1B-22-20000 group, with 10 groups in each group and half male and half female. Each group was treated or administered drugs as follows.

[0105] Normal group: Administered an equal volume of sodium carboxymethyl cellulose;

[0106] Blank control group: Administered an equal volume of sodium carboxymethyl cellulose;

[0107] Icariin group: intraperitoneal injection of 1 mg / kg icariin;

[0108] Formula I group: Intraperitoneal injection of 1 mg / kg of Formula I compound;

[0109] Group W-1B-22-600: Intraperitoneal injection of 0.1 mg / kg of compound W-1B-22-600;

[0110] Group W-1B-22-4000: Intraperitoneal injection of 0.1 mg / kg of compound W-1B-22-4000;

[0111] Group W-1B-22-20000: Intraperitoneal injection of 0.1 mg / kg of compound W-1B-22-20000;

[0112] Each treatment group was administered the drug once daily and fed normally. After 10 consecutive days of administration, mice were anesthetized, blood was collected, and the numbers of white blood cells and platelets were measured to investigate the effect of the compound of this invention on white blood cells and platelets.

[0113] 2. Experimental Results

[0114] Through this embodiment, the various compounds of the present invention are used to accept... 60 The effects of Co radiation on white blood cells and platelets in mice (Table 3) revealed that the compounds of this invention have an unexpected effect in alleviating radiotherapy-induced bone marrow suppression.

[0115] Compared with the model control group, the total number of white blood cells and the total number of platelets in each compound group of the present invention were increased, and the differences were significant.

[0116] Compared with the icariin group, the total number of white blood cells and platelets in each compound group of the present invention increased significantly.

[0117] Compared with Formula I, the total number of white blood cells and the total number of platelets in each compound group of the present invention are significantly increased.

[0118] Table 3. Pairs of each compound 60 Effect of Co-irradiated mice on blood cell count

[0119]

[0120] Compared with the blank control group, $ p<0.05, $$ p<0.01;

[0121] Compared with the icariin group, # p<0.05, ## p<0.01;

[0122] Compared with Equation I, & p<0.05, && p<0.01.

[0123] Example 17 Inhibitory effect of the compounds of the present invention on airway smooth muscle

[0124] Airway remodeling is an important pathological feature of bronchial asthma, and airway smooth muscle cells (ASMCs) are the main effector cells causing airway remodeling. Compared with normal individuals, patients with severe asthma have significantly increased ASMC levels, a phenomenon mainly caused by smooth muscle cell proliferation.

[0125] 1.1 Materials

[0126] 150–200 g SD rats; DMEM medium (Gibico); fetal bovine serum (Hangzhou Sijiqing Co., Ltd.); trypsin (Sigma).

[0127] 1.2 Experimental Methods

[0128] 1.2.1 Culture of rat ASM C

[0129] Following the method described in relevant literature: Under aseptic conditions, the trachea was longitudinally dissected, the outer membrane was carefully peeled off, and the inner membrane was gently scraped away. The tracheal segment was carefully cut into small tissue blocks (1mm × 1mm × 1mm) using ophthalmic scissors. These blocks were then placed on the bottom of a 5cm × 5cm culture flask, arranged at equal intervals. 2mL of DMEM (high glucose) medium containing 25% fetal bovine serum was added, ensuring the culture medium did not contact the tissue blocks. The culture flask was placed bottom-up and incubated at 37°C with 5% carbon dioxide for approximately 3 hours to allow the tissue blocks to nearly dry. The culture flask was then gently inverted so that the culture medium just covered the surface of the tissue blocks. After 3 days of semi-open, absolutely static culture, the culture medium was added to 5mL. The medium was completely changed after 6 days, and thereafter changed every 3 days. After approximately 7 days, the cells reached confluence and were passaged. Cells from passages 4-5 were used in the experiment. The cultured rat ASMCs were identified morphologically.

[0130] 1.2.2 Detection of ASMC proliferation in rats using the CCK-8 assay

[0131] Fourth-generation rat ASMCs were cultured and prepared into a single-cell suspension, at a concentration of 1×10⁻⁶ cells / cells. 4 Cells were seeded per well in a 96-well plate and cultured at 37°C with 5% carbon dioxide for 24 hours. When the cells reached a confluent state, culture medium containing 0.1% fetal bovine serum was added (to arrest cell growth in the G0 phase) and the cells were cultured for another 24 hours.

[0132] The culture medium was replaced with one containing 1% fetal bovine serum, and the cells were randomly divided into:

[0133] Control group: DMEM was added to each well only;

[0134] The icariin group, with an icariin concentration of 1×10⁻⁶. -6 mol / L;

[0135] Formula I group: The concentration of compound I is 1×10 -6 mol / L;

[0136] Group W-1B-22-600: The concentration of compound W-1B-22-600 is 1×10⁻⁶. -6 mol / L;

[0137] Group W-1B-22-4000: The concentration of compound W-1B-22-4000 is 1×10 -6 mol / L;

[0138] Group W-1B-22-20000: The concentration of compound W-1B-22-20000 is 1×10 -6 mol / L;

[0139] Each group had 5 replicates, and each group also included a control group (containing no cells, but with the same DMEM concentration as the corresponding group). After culturing at 37℃ and 5% CO2 for 48 h, 10 μL of CCK-8 reagent was added to each well, and the cells were cultured for another 4 h. The OD value of each well was measured at a wavelength of 450 nm. The cell growth inhibition rate of each group was calculated using the formula: Cell growth inhibition rate = 1 - [(OD value of each drug-treated group - OD value of the corresponding control group) / (OD value of the control group - OD value of the corresponding control group)] × 100%.

[0140] 2 Results

[0141] 2.1 Identification of ASMC

[0142] Observation with an inverted phase contrast microscope revealed that ASMCs were spindle-shaped before merging, and after merging, cells in some areas were arranged in bundles, exhibiting a typical "peak and valley" shape.

[0143] 2.2 Effects on ASMC proliferation

[0144] After 48 hours of treatment with ASMCs, the OD values ​​of the cells in each compound group of the present invention were significantly lower than those in the icariin group, with statistically significant differences.

[0145] Compared with the icariin group of cells, the inhibition rate of all groups of cells in this invention was significantly increased, and the differences were statistically significant.

[0146] Compared with the cells of the Formula I group, the inhibition rates of the cells in each group treated with the compounds of the present invention are all significantly increased, with statistically significant differences (see Tables 4 and 5).

[0147] Table 4 OD values of ASMC treated with each compound for 48 h

[0148]

[0149] Compared with the normal control group, $ p<0.05, $$ p<0.01;

[0150] Compared with the icariin aglycone group, # p<0.05, ## p<0.01;

[0151] Compared with the Formula I group, & p<0.05, && p<0.01.

[0152] Table 5 Inhibition rates of ASMC treated with each compound for 48 h

[0153]

[0154] Compared with the icariin aglycone group, $ p<0.05, $$ p<0.01;

[0155] Compared with the Formula I group, & p<0.05, && p<0.01.

[0156] Example 18 Determination of bioavailability of the compounds of the present invention

[0157] 1. Animal grouping and administration

[0158] 60 Wistar rats weighing (270±30) g, half male and half female, were provided by the Laboratory Animal Center of Shandong New Time Pharmaceutical Co., Ltd., with the production license number: SCXK (Lu) 20060019. The rats were raised under the conditions of temperature 20-22°C, relative humidity 45%-65%, light / dark 12h / 12h, with free access to food and water.

[0159] The compound administration group of this invention via gavage: Thirty healthy Wistar rats (half male and half female) that had been fasted for 12 hours and had free access to water were divided into 5 groups: icariin group (icariin administered via gavage), Formula I group (compound of Formula I administered via gavage), W-1B-22-600 group (compound W-1B-22-600 administered via gavage), W-1B-22-4000 group (compound W-1B-22-4000 administered via gavage), and W-1B-22-20000 group (compound W-1B-22-20000 administered via gavage). Each group received a single gavage dose of 3 mg / kg. The rats were fasted for 12 hours prior to administration but had free access to water. Blood samples of approximately 300 μL were collected from the retro-orbital venous plexus at 0 h before drug administration and at 0.083, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 h after drug administration. The blood was anticoagulated with heparin, centrifuged at 12,000 rpm for 5 min at 4 °C, and the plasma was separated and stored at -20 °C. Patients had free access to water during the experiment and were given food 2 h after gavage.

[0160] The intravenous administration group of the compounds of this invention: Thirty healthy Wistar rats, half male and half female, which had been fasted for 12 hours and had free access to water, were divided into 5 groups: icariin group (administered by injection of icariin), Formula I group (administered by injection of compound I), W-1B-22-600 group (administered by injection of compound W-1B-22-600), W-1B-22-4000 group (administered by injection of compound W-1B-22-4000), and W-1B-22-20000 group (administered by injection of compound W-1B-22-20000). All groups were administered the compound via tail vein injection at a dose of 3 mg / kg. Blood samples of approximately 300 μL were collected from the posterior orbital venous plexus at 0 h before drug administration and at 0.033, 0.083, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 h after drug administration. The blood was anticoagulated with heparin, centrifuged at 12,000 rpm for 5 min at 4°C, and the plasma was separated and stored at -20°C. Free access to food and water was allowed during the experiment.

[0161] 2. Plasma sample testing

[0162] All processed plasma samples were subjected to UPLC-MS / MS quantitative analysis to determine plasma drug concentration.

[0163] 3. Calculation of bioavailability

[0164] The measured blood drug concentration-time data were used to calculate pharmacokinetic parameters using DAS software (Drug and Statistics, compiled by Sun Ruiyuan et al., Chinese Society for Mathematical Pharmacology). The absolute bioavailability of each compound was calculated according to the formula, where t is the sampling time at which the final measurable drug concentration was obtained.

[0165]

[0166] 4. Absolute bioavailability of each compound

[0167] Table 6 Bioavailability of each compound

[0168]

[0169] As can be seen from the table above, the bioavailability of each compound in this invention is significantly higher than that of icariin and compound I, indicating that the compounds in this invention have significant technical advantages in terms of drug-likeness.

[0170] Example 19: Repeated-injection toxicity study of compounds W-1B-22-600, W-1B-22-4000, W-1B-22-20000 and compound I of the present invention in rats.

[0171] SD rats were divided into five groups: normal control group, compound I group (intravenous injection of compound I 100 mg / kg / d), W-1B-22-600 group (intravenous injection of W-1B-22-600 100 mg / kg / d), W-1B-22-4000 group (intravenous injection of W-1B-22-4000 100 mg / kg / d), and W-1B-22-20000 group (intravenous injection of W-1B-22-20000 100 mg / kg / d).

[0172] Animals in each group were administered the drug continuously for 28 days, once daily, followed by a 4-week recovery period after drug withdrawal. At the end of the treatment period, blood samples were collected from the abdominal main vein for hematological, coagulation time, blood biochemistry, and electrolyte analysis. Subsequently, a systematic dissection was performed to observe the morphology of each organ and tissue. The brain, spleen, thymus, heart, kidneys (bilateral), liver, adrenal glands (bilateral), mammary glands (female rats), and prostate (male rats) were weighed, and organ coefficients were calculated.

[0173] Experiments revealed elevated levels of creatinine, alkaline phosphatase, and alanine aminotransferase in rats treated with compound I. Histopathological examination showed varying degrees of renal tubular damage, indicating significant nephrotoxicity. Mammary hyperplasia was observed in female rats. Compound I exhibited certain toxic side effects.

[0174] Under the conditions of this experiment, no abnormal changes related to the toxicity of W-1B-22-600 were found. W-1B-22-600 injection administration showed no obvious toxicity and has a high safety profile for clinical use.

[0175] Under the conditions of this experiment, no abnormal changes related to the toxicity of W-1B-22-4000 were found. W-1B-22-4000 injection administration showed no obvious toxicity and has a high safety profile for clinical use.

[0176] Under the conditions of this experiment, no abnormal changes related to the toxicity of W-1B-22-20000 were found. Injection administration of W-1B-22-20000 showed no significant toxicity, and its clinical use is highly safe.

Claims

1. An icariin derivative, the structure of which is shown in formula W-1B: , or a pharmaceutically acceptable salt of the compound of formula W-1B; in, The m and n are independently selected from integers from 0 to 4; The molecular weight of the PEG is selected from 400-20000.

2. The icariin derivative as described in claim 1, characterized in that, The molecular weight of the PEG is selected from 1000-10000.

3. The icariin derivative as described in claim 1, characterized in that, The molecular weight of the PEG is selected from PEG400, PEG600, PEG1000, PEG2000, PEG3000, PEG4000, PEG6000, PEG10000 or PEG20000.

4. The icariin derivative as described in claim 1, characterized in that, The compound of formula W-IB is specifically compound W-IB-22: 。 5. The icariin derivative as described in claim 1, characterized in that, The W-IB compound is specifically: , , , , , , , ,or .

6. The icariin derivative as described in claim 1, characterized in that, The synthetic steps of the W-IB compound are as follows: 1) Boc-ICT reacts with haloalcohols to give 1; ; 2) Compound 1 reacts with Boc2O to give compound 2; ; 3) Compound 2 was deprotected to give compound 3 ; 4) PEG and The reaction yields 4; ; 5) Compound 3 and compound 4 react in the presence of a condensing agent to form compound 5: ; 6) Compound 5 was deprotected to give compound W-1B; .

7. The icariin derivative as described in claim 6, characterized in that, The condensing agent is selected from at least one of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride / 4-dimethylaminopyridine (EDCI / DMAP), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride / 1-hydroxybenzotriazole / N,N-diisopropylethylamine (EDCI / HOBT / DIPEA), 2-(7-benzotriazole oxide)-N,N,N',N'-tetramethylurea hexafluorophosphate / N,N-diisopropylethylamine (HATU / DIPEA), and dicyclohexylcarbodiimide / 4-dimethylaminopyridine (DCC / DMAP).

8. A pharmaceutical composition comprising the icariin derivative of any one of claims 1-5 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

9. Use of the pharmaceutical composition of claim 8 in the preparation of a medicament for treating asthma or myelosuppression.

Citation Information

Patent Citations

  • Therapeutic agents for adiposity or fatty liver

    CN101284000A

  • Uses of icaritin in preparing medicament for preventing and treating endotoxemia

    CN101428015A

  • Application of icaritin in preparation of anti-angiogenic medicaments

    CN101836976A

  • Use of icariin in inducting dry cell body in-vitro directional differentiation

    CN1869204A

  • Pegylated glycosides of aerial parts of epimedium, and preparation and use thereof

    CN101297974A